Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099890 | 0.83 | NOTUM (0.54) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL32673770 | 0.82 | NOTUM (0.54) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL7140297 | 0.82 | NOTUM (0.54) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL8527054 | 0.81 | NOTUM (0.53) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL30727224 | 0.80 | GPR119 (0.48) | NOTUM | |
| SCHEMBL17795342 | 0.80 | GPR119 (0.48) | NOTUM | |
| SCHEMBL8785820 | 0.80 | NOTUM (0.51) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL8148793 | 0.79 | NOTUM (0.54) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL21469189 | 0.79 | NOTUM (0.58) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 | |
| SCHEMBL8530059 | 0.79 | HTR2A (0.57) | NOTUMCYP11B2CYP11B1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-7109201-B2 | Piperazine derivatives, their preparation and uses in therapy | SMITHKLINE BEECHAM PLC (GB) | 2006-09-19 | — | — | US | disclosed |
| EP-1368337-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | disclosed |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-22 | — | — | US | disclosed |
| US-6747030-B1 | CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
| EP-1368337-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002074764-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-09-26 | — | — | WO | disclosed |
| EP-1216239-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023374-A1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | HTR1B, HTR2B, HTR2A | NOTUM 4293/4885CYP11B2 970/4885CYP11B1 939/4885 |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | NR3C2, NR2C2, NR3C1 | NOTUM 2465/4885CYP11B2 273/4885CYP11B1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.